These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20711837)

  • 1. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study.
    Pech M; Janitzky A; Wendler JJ; Strang C; Blaschke S; Dudeck O; Ricke J; Liehr UB
    Cardiovasc Intervent Radiol; 2011 Feb; 34(1):132-8. PubMed ID: 20711837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible electroporation (IRE): a novel method for renal tissue ablation.
    Tracy CR; Kabbani W; Cadeddu JA
    BJU Int; 2011 Jun; 107(12):1982-7. PubMed ID: 21044244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
    Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
    Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).
    Wendler JJ; Pech M; Fischbach F; Jürgens J; Friebe B; Baumunk D; Porsch M; Blaschke S; Schindele D; Siedentopf S; Ricke J; Schostak M; Köllermann J; Liehr UB
    Urology; 2018 Apr; 114():224-232. PubMed ID: 29305201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study.
    Wendler JJ; Pech M; Köllermann J; Friebe B; Siedentopf S; Blaschke S; Schindele D; Porsch M; Baumunk D; Jürgens J; Fischbach F; Ricke J; Schostak M; Böhm M; Liehr UB
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):466-476. PubMed ID: 28929209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial.
    Wendler JJ; Ricke J; Pech M; Fischbach F; Jürgens J; Siedentopf S; Roessner A; Porsch M; Baumunk D; Schostak M; Köllermann J; Liehr UB
    Cardiovasc Intervent Radiol; 2016 Feb; 39(2):239-50. PubMed ID: 26341653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irreversible electroporation for the ablation of liver tumors: are we there yet?
    Charpentier KP
    Arch Surg; 2012 Nov; 147(11):1053-61. PubMed ID: 23165618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo results of a new focal tissue ablation technique: irreversible electroporation.
    Edd JF; Horowitz L; Davalos RV; Mir LM; Rubinsky B
    IEEE Trans Biomed Eng; 2006 Jul; 53(7):1409-15. PubMed ID: 16830945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible electroporation ablation: is all the damage nonthermal?
    Faroja M; Ahmed M; Appelbaum L; Ben-David E; Moussa M; Sosna J; Nissenbaum I; Goldberg SN
    Radiology; 2013 Feb; 266(2):462-70. PubMed ID: 23169795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and safety of irreversible electroporation (IRE) in patients with small renal masses: Results of a prospective study.
    Buijs M; Zondervan PJ; de Bruin DM; van Lienden KP; Bex A; van Delden OM
    Urol Oncol; 2019 Mar; 37(3):183.e1-183.e8. PubMed ID: 30509869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irreversible Electroporation for the Treatment of Small Renal Masses: 5-Year Outcomes.
    Dai JC; Morgan TN; Steinberg RL; Johnson BA; Garbens A; Cadeddu JA
    J Endourol; 2021 Nov; 35(11):1586-1592. PubMed ID: 33926224
    [No Abstract]   [Full Text] [Related]  

  • 12. Percutaneous radiofrequency ablation of renal tumors in solitary kidney patients.
    Jiménez E; Zurera L; Espejo JJ; Requena MJ; Campos P; Rodríguez de Tembleque L; Canis M
    Arch Esp Urol; 2011; 64(1):51-8. PubMed ID: 21289386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary study to delineate irreversible electroporation from thermal damage using the arrhenius equation.
    Shafiee H; Garcia PA; Davalos RV
    J Biomech Eng; 2009 Jul; 131(7):074509. PubMed ID: 19640145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time virtual ultrasonographic radiofrequency ablation of renal cell carcinoma.
    Ukimura O; Mitterberger M; Okihara K; Miki T; Pinggera GM; Neururer R; Peschel R; Aigner F; Gradl J; Bartsch G; Colleselli D; Strasser H; Pallwein L; Frauscher F
    BJU Int; 2008 Mar; 101(6):707-11. PubMed ID: 18205858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and mid-term effects of irreversible electroporation on normal renal tissue: an animal model.
    Wendler JJ; Porsch M; Hühne S; Baumunk D; Buhtz P; Fischbach F; Pech M; Mahnkopf D; Kropf S; Roessner A; Ricke J; Schostak M; Liehr UB
    Cardiovasc Intervent Radiol; 2013 Apr; 36(2):512-20. PubMed ID: 22893419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasound guided percutaneous microwave ablation for small renal cancer: initial experience.
    Liang P; Wang Y; Zhang D; Yu X; Gao Y; Ni X
    J Urol; 2008 Sep; 180(3):844-8; discussion 848. PubMed ID: 18635230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous radiofrequency thermal ablation of renal cell carcinoma: is it possible a day-hospital treatment?
    Carrafiello G; Laganà D; Ianniello A; Mangini M; Fontana F; Cotta E; Concollato L; Marconi A; Recaldini C; Dionigi G; Rovera F; Boni L; Cuffari S; Fugazzola C
    Int J Surg; 2008; 6 Suppl 1():S31-5. PubMed ID: 19200792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrode activation sequencing employing conductivity changes in irreversible electroporation tissue ablation.
    Sahakian AV; Al-Angari HM; Adeyanju OO
    IEEE Trans Biomed Eng; 2012 Mar; 59(3):604-7. PubMed ID: 22194234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protecting the ureter during radiofrequency ablation of renal cell cancer: a pilot study of retrograde pyeloperfusion with cooled dextrose 5% in water.
    Cantwell CP; Wah TM; Gervais DA; Eisner BH; Arellano R; Uppot RN; Samir AE; Irving HC; McGovern F; Mueller PR
    J Vasc Interv Radiol; 2008 Jul; 19(7):1034-40. PubMed ID: 18589317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Image-guided biopsy-diagnosed renal cell carcinoma: critical appraisal of technique and long-term follow-up.
    Somani BK; Nabi G; Thorpe P; N'Dow J; Swami S; McClinton S;
    Eur Urol; 2007 May; 51(5):1289-95; discussion 1296-7. PubMed ID: 17081679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.